Advertisement

Neuroprotektive Strategien bei neurodegenerativen Erkrankungen — was haben wir gelernt?

  • A. C. Ludolph
Conference paper
  • 68 Downloads

Zusammenfassung

Was ist Neuroprotektion? Eine einleuchtende Definition neuroprotektiver Strategien wurde von Ira Shoulson gegeben[23]:„Neuroprotective strategies ate pharmacological interventions that produce enduring benefits by favourably influencing underlying etiology or pathogenesis and thereby forestalling onset of disease or clinical decline“. Es handelt sich bei dieser Definition um eine Herangehenweise an Neuroprotektion, die sich vor allem auf pharmakologische Strategien erstreckt. Dies schießt keine Strategien mit ein, die allein der Prävention dienen; so zum Beispiel die Phenylalaninrestriktion in der Behandlung der Phenylketonurie, die Behandlung des M. Wilson mit Chelatoren oder gar die Polioimpfung, die ja eindrucksvoll vor dem verlust von Motoneuronen schützt. Darüber hinaus bedeutet das Wort „enduring“, dass sich diese Strategien von rein symptomatischen Therapieansätzen wie der L-Dopa-Therapie des M. Parkinson unterscheiden. Schließlich fordert diese Definition, dass neuroprotektive Strategien entweder die Ätiologie oder die Pathogenese degenerativer Erkrankungen beeinflussen, also eine besonderes hohe Hürde dar, da wir bei vielen degenerativen Erkrankungen des zentralen Nervensystems die Ursache nur inkomplett kennen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Andrews TC, Weeks RA, Turjanski N, Gunn RN, Watkins LH, Sahakian B, Hodges JR, Rosser AE, Wood NW, Brooks DJ (1999) Huntington’s disease progressions. Brain 122: 2353–2363PubMedCrossRefGoogle Scholar
  2. 2.
    Bensimon G, Lacomblez L, Meininger V and the ALS/Riluzole Study Group (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 330: 585–591CrossRefGoogle Scholar
  3. 3.
    Bensimon G, Leigh PN, Ludolph A, Lacomblez L, Vidailhet M; Landwehrmeyer B, Burn D, Dib M, Zierz S, Meininger V, Lees A, Agid Y & The NNIPPS Study Group (2002) Neuroprotection and natural history in Parkinson Plus Syndromes (NNIPPS): Design & progress report of a clinical trial of the efficacy and safety of riluzole in progressive supranuclear palsy (PSP) and multiple system atrophy (MSA). International Movement Disorders Congress, MiamiGoogle Scholar
  4. 4.
    Foltynie T, Brayne C, Barker RA (2002) The heterogenity of idiopathic Parkinson’s disease. J Neurol 249: 138–145PubMedCrossRefGoogle Scholar
  5. 5.
    Gurney ME, Pu H, Chiu A, Dal Canto M, Polchow C, Alexander D, Caliendo J, Hantati A, Kwon Y, Deng H, Chen W, Zhai P, Sifit R, Siddique T (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264: 1773–1775CrossRefGoogle Scholar
  6. 6.
    Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39: 147–157PubMedCrossRefGoogle Scholar
  7. 7.
    Huang S, Li B, Gray MD, Oshima J, Mian IS, Campisi J (1998) The premature ageing syndrome protein, WRN, is a 3’-5’exonuclease. Nature Genetics 20: 114–116PubMedCrossRefGoogle Scholar
  8. 8.
    Karitzky J, Ludolph AC (2001) Imaging and Neurochemical Markers for Diagnosis and Disease Progression in ALS, J Neurol Science (191): 35–41Google Scholar
  9. 9.
    Kong J, Xu Z (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J Neurosci 8: 3241–3250Google Scholar
  10. 10.
    Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet 347: 1425–1431PubMedGoogle Scholar
  11. 11.
    Lynch DR, Farmer JM, Balcer LJ, Wilson RB (2002) Friedreich ataxia: effects of genetic understanding on clinical evaluation and therapy. Arch Neurol 58: 743–747CrossRefGoogle Scholar
  12. 12.
    Martin GM, Oshima J (2000) Lessons from human progeroid syndromes. Nature 408: 263–269PubMedCrossRefGoogle Scholar
  13. 13.
    Morrish PK, Sawle GV, Brooks DJ (1996) An (18F)dopa PET and clinical study of the rate of progression in Parkinson’s disease. Brain 119: 585–591PubMedCrossRefGoogle Scholar
  14. 14.
    Morrison JH, Hof PR (1997) Life and death of neurons in the aging brain. Science 278: 412–419PubMedCrossRefGoogle Scholar
  15. 15.
    Mouradian MM (2002) Recent advances in the genetics and pathogenesis of Parkinson’s disease. Neurology 58: 179–185PubMedCrossRefGoogle Scholar
  16. 16.
    Munch C, Zhu BG, Schwalenstocker B, Seefried U, Ludolph AC, Meyer T (2001) Regulation of RNA splicing of the glutamate transporter EAAT2 in the preclinical course of a transgenic mouse model for amyotrophic lateral sclerosis. Journal of NeurochemistryGoogle Scholar
  17. 17.
    Parkinson Study Group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson’s disease progression. JAMA 287: 1653–1661CrossRefGoogle Scholar
  18. 18.
    Price DL, Sisodia SS, Borchelt DR (1998) Genetic neurodegenerative diseases: The human illness and transgenic models. Science 282: 1079–1083PubMedCrossRefGoogle Scholar
  19. 19.
    Riviere M, Meininger V, Zeisser P, Munsat T (1998) An analysis of extended survival in patients with amyotrophic lateral sclerosis treated with riluzole. Arch Neurol 55: 526–528PubMedCrossRefGoogle Scholar
  20. 20.
    Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362: 59–62PubMedCrossRefGoogle Scholar
  21. 21.
    Rustin P, von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig A (1999) Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet 354: 477–479PubMedCrossRefGoogle Scholar
  22. 22.
    Schwarz J, Linke R, Kerner M, Mozley PD, Trenkwalder C, Gasser T, Tatsch K (2000) Striatal dopamine transporter binding assessed by (I-23)IPT and single photon emission computed tomography in patients with early Parkinson’s disease: Implications for a preclinical diagnosis. Arch Neurol 57: 205–208PubMedCrossRefGoogle Scholar
  23. 23.
    Shoulson I (1998) Experimental therapeutics of neurodegenerative disorders: unmet needs. Science 282: 1072–1074PubMedCrossRefGoogle Scholar
  24. 24.
    Sleegers K, Van Duijn CM (2001) Alzheimer’s Disease: Genes, Pathogenesis and Risk Prediction. Community Genet 4: 197–203PubMedCrossRefGoogle Scholar
  25. 25.
    Storch A, Burkhardt K, Ludolph AC, Schwarz J (2000) Protective effects of riluzole on dopamine neurons: Involvement of oxidative stress and cellular energy metabolism. J Neurochem 75: 2259–2269PubMedCrossRefGoogle Scholar
  26. 26.
    The EHDI Trial Group: the effect of riluzole 50 mg BID over a period of three years on the progression of Huntington’s disease. Protocol. SubmittedGoogle Scholar
  27. 27.
    Traynor BJ, Alexander M, Corr B, Frost E, Mahon L, Hardman 0 (2001) Riluzole and prognosis in amyotrophic lateral sclerosis: Findings of the Irish amyotrophic lateral sclerosis register over a five year study period 1995–2000. ALS and other motor neuron disorders 2 (Suppl 2): 1995–2000Google Scholar
  28. 28.
    Tumani H, Windl O, Kretzschmar HA, Ludolph AC (2001) Die klinisch atypische CJK - Diagnostische Bedeutung von Liquormarkern und molekulargenetischen Untersuchungen? Deutsche Medizinische Wochenschrift 127: 317–320Google Scholar
  29. 29.
    Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A (2002) Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. ALS and other motor neuron disorders 3: 15–21PubMedGoogle Scholar
  30. 30.
    Vogt C, Vogt O (1922) Erkrankungen der Groghirnrinde. Journal fur Psychologie und Neurologic 28: 8–171Google Scholar
  31. 31.
    von Arnim C, Ludolph AC (2001) Normales und pathologisches Altern des Gehirns. Fortschr Med 118: 165–168Google Scholar
  32. 32.
    Whone AL, Remy P, Davis MR, Sabolek M, Nahmias C, Stoessl J, Watts RL, Brooks DJ (2002) The REAL-PET Study: slower progression in early Parkinson’s disease treated with ropinirole compared with L-dopa. Neurology 59: A82–A83Google Scholar
  33. 33.
    Yamamoto A, Lucas JJ, Hen R (2000) Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell 101: 57–66PubMedCrossRefGoogle Scholar
  34. 34.
    Xu Z (2000) Mechanism and treatment of motoneuron degeneration in ALS: What have SOD1 mutants told us? ALS and other motor neuron disorders 1: 225–234PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • A. C. Ludolph

There are no affiliations available

Personalised recommendations